Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.

Cancer immunology, immunotherapy : CII - 1 Jul 2021

Abdel-Wahab Noha, Diab Adi, Yu Robert K, Futreal Andrew, Criswell Lindsey A, Tayar Jean H, Dadu Ramona, Shannon Vickie, Shete Sanjay S, Suarez-Almazor Maria E

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICIs) can cause profound immune-related adverse events (irAEs). The host genetic background is likely to play a role in irAE susceptibility because the presentation of toxicity varies among patients and many do not develop irAEs despite continued ICI use. We sought to identify potential genetic markers conferring risk for irAEs. METHODS: We conducted a pilot exploratory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug-Related Side Effects and Adverse Reactions
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Markers

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Pilot Projects

Share to Prognosis

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 33409738
DOI: 10.1007/s00262-020-02797-0
PMCID: PMC10992432

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.PMID 33409738Read ↗

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicitySemantic proximity Read ↗

Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsSemantic proximity Read ↗

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approachSemantic proximity Read ↗

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.Semantic proximity Read ↗

Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.Semantic proximity Read ↗

Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitorsSemantic proximity Read ↗

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.Semantic proximity Read ↗

Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanomaSemantic proximity Read ↗

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse eventsSemantic proximity Read ↗

Phenotypic insights into genetic risk factors for immune-related adverse events in cancer immunotherapy.Semantic proximity Read ↗

Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical SettingSemantic proximity Read ↗

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 MonotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.